Printer Friendly

Articles from M2 Pharma (October 10, 2018)

1-24 out of 24 article(s)
Title Author Type Words
3M introduces new advanced surgical skin prep solution to fight against SSIs. 186
Ablexis Inks Licensing Agreement with Memorial Sloan Kettering Cancer Center. 251
Appili Therapeutics Appoints Infectious Disease Global Drug Development Executive to Its Board of Directors. 504
Bial and Eisai confirm Zebinix as monotherapy in Euro-Esli study. 153
BioDuro establishes new California drug discovery centre for chemistry and biology. 157
c-LEcta Signs Europe Sales and Distribution Agreement with VWR for Denarase. 306
Cantargia to present interim results of clinical data from ongoing CANFOUR trial at ESMO in Munich, Germany. 348
Celgene Touts Results of Phase 3 STYLE Study of Otezla in Moderate to Severe Scalp Psoriasis Met Primary Endpoint. 499
eTheRNA immunotherapies opens Belgium mRNA facility. 156
European Medicines Accepts Drug Application for Aerie Pharmaceuticals' Rhokiinsa. 322
GenAhead Bio and ERS Genomics Enter into CRISPR/Cas9 License Agreement. 401
Genentech to Present New Positive Data from Its Broad Cancer Immunotherapy Programme. 725
Genmab and Seattle Genetics to present data on tisotumab vedotin at ESMO 2018 Congress in Munich, Germany. 447
Inovio Pharmaceuticals completes animal testing of DNA-encoded monoclonal antibodies. 271
MedMen to acquire first dispensary in San Francisco Bay Area to expand footprint into Northern California. 196
National Comprehensive Cancer Network Adds Verastem Oncology's Copiktra Capsules to Clinical Practice Guidelines in Oncology for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. 540
Neurocrine Biosciences partners with Jnana Therapeutics to discover novel medicines to treat central nervous system disorders. 242
NeuroVive Pharmaceutical announces receipt of KL1333 clinical trial regulatory approval from MHRA in UK. 234
Pri-Med partners with BAF to develop, educate & update primary health care providers in brain aneurysm awareness. 230
Qualigen receives US FDA 510(k) acknowledgement for FastPack IP SHBG Immunoassay. 161
Revolution Medicines: First Patient Dosed with RMC-4630 in Phase 1 Clinical Study in Patients with Advanced Solid Tumors. 552
TerrAscend names new chief corporate officer. 112
Vapotherm announces US FDA approval for new category Vapotherm Hi-VNI system, with world-wide launch by January 2019. 323
Veracyte Presents Data Confirming Envisia Genomic Classifier's Ability to Improve Diagnosis of Idiopathic Pulmonary Fibrosis. Clinical report 530

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters